Shafaat A Rabbani


Affiliation: McGill University
Country: Canada


  1. Rabbani S, Ateeq B, Arakelian A, Valentino M, Shaw D, Dauffenbach L, et al. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010;12:778-88 pubmed
    ..Results from these studies provide compelling evidence for the continued development of ATN-658 as a potential therapeutic agent for the treatment of prostate and other cancers expressing uPAR. ..
  2. Rabbani S, Valentino M, Arakelian A, Ali S, Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 2010;9:1147-57 pubmed publisher
    ..SKI-606 is currently in clinical trials for breast cancer and chronic myelogenous leukemia. Results from these studies provide convincing evidence for evaluating its efficacy in prostate cancer patients. ..
  3. Parashar S, Cheishvili D, Mahmood N, Arakelian A, Tanvir I, Khan H, et al. DNA methylation signatures of breast cancer in peripheral T-cells. BMC Cancer. 2018;18:574 pubmed publisher
    ..The study points to the possibility of using DNA methylation signatures as a noninvasive method for early detection of breast cancer and its progression which need to be tested in clinical studies. ..